The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104)

Goldstraw, 2016, The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer, J Thorac Oncol, 11, 39, 10.1016/j.jtho.2015.09.009 Booth, 2012, Adjuvant chemotherapy for non–small cell lung cancer: practice patterns and outcomes in the general population of Ontario, Canada, J Thorac Oncol, 7, 559, 10.1097/JTO.0b013e31823f43af Ou, 2010, Adjuvant carboplatin-based chemotherapy in resected stage IIIA-N2 non–small cell lung cancer, J Thorac Oncol, 5, 1033, 10.1097/JTO.0b013e3181d95db4 Williams, 2014, Use and impact of adjuvant chemotherapy in patients with resected non–small cell lung cancer, Cancer, 120, 1939, 10.1002/cncr.28679 Douillard, 2008, Int J Radiat Oncol Biol Phys, 72, 695, 10.1016/j.ijrobp.2008.01.044 Lally, 2006, Postoperative radiotherapy for stage II or III non–small-cell lung cancer using the surveillance, epidemiology, and end results database, J Clin Oncol, 24, 2998, 10.1200/JCO.2005.04.6110 Pignon, 2008, Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group, J Clin Oncol, 26, 3552, 10.1200/JCO.2007.13.9030 Shi, 2014, A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non–small-cell lung cancer of adenocarcinoma histology (PIONEER), J Thorac Oncol, 9, 154, 10.1097/JTO.0000000000000033 Vansteenkiste, 2013, Early and locally advanced non–small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 24, vi89, 10.1093/annonc/mdt241 Wu, 2015, First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non–small-cell lung cancer: analyses form the phase III, randomized, open-label, ENSURE study, Ann Oncol, 26, 1883, 10.1093/annonc/mdv270 Goss, 2013, Gefitinib versus placebo in completely resected non–small-cell lung cancer: results of the NCIC CTG BR19 study, J Clin Oncol, 31, 3220, 10.1200/JCO.2013.51.1816 Kelly, 2008, Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non–small-cell lung cancer: SWOG S0023, J Clin Oncol, 26, 2450, 10.1200/JCO.2007.14.4824 D’Angelo, 2012, Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib, J Thorac Oncol, 7, 1815, 10.1097/JTO.0b013e31826bb7b2 Zhong, 2018, Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study, Lancet Oncol, 19, 139, 10.1016/S1470-2045(17)30729-5 Hattori, 2017, Prognostic impact of the findings on thin-section computed tomography in patients with subcentimeter non-–small cell lung cancer, J Thorac Oncol, 12, 954, 10.1016/j.jtho.2017.02.015 Lampaki, 2015, Defining the role of tyrosine kinase inhibitors in early stage non–small cell lung cancer, J Cancer, 6, 568 Sugimura, 2007, Survival after recurrent non–small-cell lung cancer after complete pulmonary resection, Ann Thorac Surg, 83, 409, 10.1016/j.athoracsur.2006.08.046 Colt, 2013, Follow-up and surveillance of the patient with lung cancer after curative-intent therapy: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines, Chest, 143, e437S, 10.1378/chest.12-2365 Wong, 2016, Impact of age and comorbidity on treatment of non–small cell lung cancer recurrence following complete resection: a nationally representative cohort study, Lung Cancer, 102, 108, 10.1016/j.lungcan.2016.11.002 Yue, 2018, Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non–small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial, Lancet Respir Med, 6, 863, 10.1016/S2213-2600(18)30277-7 Kelly, 2015, Adjuvant erlotinib versus placebo in patients with stage IB–IIIA non–small-cell lung cancer (RADIANT): a randomized, double-blind, phase III trial, J Clin Oncol, 33, 4007, 10.1200/JCO.2015.61.8918 Hubbs, 2010, Factors associated with the development of brain metastases: analysis of 975 patients with early stage nonsmall cell lung cancer, Cancer, 116, 5038, 10.1002/cncr.25254 Park, 2018, Temporal and regional distribution of initial recurrence site in completely resected N1-stage II lung adenocarcinoma: the effect of postoperative adjuvant chemotherapy, Lung Cancer, 117, 7, 10.1016/j.lungcan.2018.01.004 Yang, 2016, AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases, Sci Transl Med, 8, 368ra172, 10.1126/scitranslmed.aag0976 Ahn, 2017, Activity and safety of AZD3759 in EGFR-mutant non–small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study, Lancet Respir Med, 5, 891, 10.1016/S2213-2600(17)30378-8 Sorensen, 1988, Brain metastases in adenocarcinoma of the lung: frequency, risk groups and prognosis, J Clin Oncol, 6, 1474, 10.1200/JCO.1988.6.9.1474 Patel, 2017, Patterns of initial and intracranial failure in metastatic EGFR-mutant non–small cell lung cancer treated with erlotinib, Lung Cancer, 108, 109, 10.1016/j.lungcan.2017.03.010 Joensuu, 2016, Adjuvant imatinib for high-risk GI stromal tumor: analysis of a randomized trial, J Clin Oncol, 34, 244, 10.1200/JCO.2015.62.9170 Jamal-Hanjani, 2017, Tracking the evolution of non–small-cell lung cancer, N Engl J Med, 376, 2109, 10.1056/NEJMoa1616288 Zhang, 2014, Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing, Science, 346, 256, 10.1126/science.1256930 Nahar, 2018, Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing, Nat Commun, 9, 10.1038/s41467-017-02584-z Chaudhuri, 2017, Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling, Cancer Discov, 7, 1394, 10.1158/2159-8290.CD-17-0716 Abbosh, 2018, Early stage NSCLC — challenges to implementing ctDNA-based screening and MRD detection, Nat Rev Clin Oncol, 15, 577, 10.1038/s41571-018-0058-3 Abbosh, 2017, Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution, Nature, 545, 446, 10.1038/nature22364 Oxnard, 2011, Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib, Clin Cancer Res, 17, 6322, 10.1158/1078-0432.CCR-11-1080